Anti-TFCP2 / Transcription factor CP2

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. TFCP2 antibody detects Transcription factor CP2, encoded by the TFCP2 gene on chromosome 12q13.12. TFCP2 antibody is used to study this ubiquitously expressed transcriptional regulator, also known as Late SV40 factor (LSF). TFCP2 controls gene expression by binding to CCAAT and GT-box elements in target promoters. It regulates structural genes, cytokines, and enzymes essential for development, hematopoiesis, and immune function. Its versatility stems from its ability to function as either an activator or repressor depending on the cellular context and partner proteins.Structurally, TFCP2 contains DNA-binding and dimerization domains that enable it to form homo- and heterodimers with related proteins such as TFCP2L1. These dimeric complexes increase its DNA-binding specificity and extend its regulatory range. In addition, TFCP2 includes transactivation and repression domains that recruit co-activators like p300 or co-repressors such as HDACs, integrating diverse signaling inputs at gene promoters. Its modular structure makes TFCP2 a flexible regulator of transcriptional programs.Functionally, TFCP2 is central to multiple biological processes. In hematopoiesis, it regulates globin gene expression and influences erythroid differentiation. In immune cells, it modulates cytokine expression, including interleukin-4 and interleukin-17, affecting immune responses and inflammation. TFCP2 also contributes to hepatic metabolism and developmental processes. Dysregulation of TFCP2 impacts immune tolerance, inflammation, and developmental outcomes. Researchers apply TFCP2 antibody to study these regulatory mechanisms in health and disease.Clinically, TFCP2 is implicated in oncogenesis. Overexpression has been observed in osteosarcoma, hepatocellular carcinoma, and other cancers, where it promotes cell survival and resistance to apoptosis. TFCP2 gene fusions have been identified in sarcomas, further supporting its oncogenic potential. Beyond cancer, TFCP2 is associated with cardiovascular and metabolic disorders. It regulates endothelial genes that influence vascular integrity and lipid metabolism. Its dysregulation has been linked to atherosclerosis, insulin resistance, and anemia. These findings highlight TFCP2's broad impact on physiology and pathology.Experimentally, TFCP2 antibody is used in western blotting to detect the ~60 kDa protein, in immunohistochemistry to examine tissue expression, and in chromatin immunoprecipitation to map binding sites across the genome. Co-immunoprecipitation with TFCP2 antibody helps identify interacting partners, clarifying its role in transcriptional networks. NSJ Bioreagents provides TFCP2 antibody to support research in cancer biology, transcriptional control, and immune regulation.